CF PharmTech Documents
Documents
0
Ticker
2652.HK
ISIN
CNE1000074R9
CF PharmTech SEC Filings
Type | Report | Date |
|---|---|---|
| No documents available | ||
CF PharmTech Documents 2026
This page contains all official documents and SEC filings for CF PharmTech stock (2652.HK, ISIN: CNE1000074R9). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 0 documents are available. Data is updated regularly to provide investors with a complete overview of CF PharmTech's regulatory filings.
CF PharmTech Stock analysis
CF PharmTech CF PharmTech Inc generates revenue through the research, development, production, and sale of pharmaceutical products targeting respiratory diseases such as asthma, COPD, and allergic rhinitis. The company's primary products are CF017, a budesonide suspension for inhalation used in bronchial asthma treatment, and CF018, an azelastine hydrochloride and fluticasone propionate nasal spray approved for allergic rhinitis. These products are sold within the domestic market, focusing on patients and healthcare providers seeking treatments for respiratory conditions. The firm's business model centers on developing and commercializing specialized respiratory medications, with CF017 and CF018 representing its core product offerings. By concentrating on respiratory diseases, the company serves a specific medical segment where demand for targeted therapies is high. Sales are driven by healthcare institutions and pharmacies within China, leveraging the domestic market's focus on respiratory health solutions. CF PharmTech Inc's revenue streams are derived from the direct sale of CF017 and CF018 to domestic healthcare providers and retail pharmacies. The company does not engage in international sales, maintaining a domestic market strategy. Product approval by regulatory authorities for specific conditions ensures market access and customer adoption within China's healthcare system.